Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ «Ставропольский государственный медицинский университет», Российская Федерация, г. Ставрополь, 355017, ул. Мира, 310; 2 Независимый исследователь в области психофармакологии, Израиль, Азур 5801726, ул. Бен-Гурион 26/7
Список исп. литературыСкрыть список 1. Perälä J, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry. 2007;64:19-28. 2. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014;2014(1):CD006569. 3. Kessler RC, et al. Age of onset of mental disorders: a review of recent literature. Curr. Opin. Psychiatry. 2007;20:359-364. 4. Sabe M, Zhao N, Crippa A, Kaiser S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ Schizophr. 2021;7(1):43. 5. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 2011;131:101-104. 6. Vermeulen J, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol. Med. 2017;47:2217-2228. 7. Casey AB, Canal CE. Classics in Chemical Neuroscience: Aripiprazole. ACS Chem Neurosci. 2017;8(6):1135-1146. 8. Беккер РА, Быков ЮВ, Морозов ПВ. Выдающиеся психиатры ХХ века. – М.: ИД «Городец», 2019. –256 с. 9. Lopez-Munoz F, Alamo C, Cuenca E et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113-135. 10. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. 5th Ed. Cambridge university press. 2021. 642 p. ISBN 978-1108838573. 11. De Hert M, Detraux J, van Winkel R et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126. 12. Banno K, Fujioka T, Kikuchi T et al. Studies on 2(1H)-quinolinone derivatives as neuroleptic agents I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives. Chem Pharm Bull (Tokyo) 1988;36(11):4377-4388. 13. Stelmach A, Guzek K, Rożnowska A, Najbar I, Sadakierska-Chudy A. Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacol Rep. 2023;75(1):19-31. 14. Ворсина ОП, Сапожникова ЕВ, Ярославцев РО, Троценко ИВ. Применение арипипразола (Абилифай) в терапии шизофрении и шизоаффективных расстройств // Психиатрия и психофармакотерапия. 2009. Т. 11. № 1. С. 34-36. 15. Simon N, Azorin JM. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact]. Encephale. 2018;44(6):558-564. 16. European Medicines Agency—EMA. Abilify (aripiprazole): summary of product characteristics. 2009. 17. Mailman RB, Murthy V. Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity? Curr Pharm Des. 2010;16(5):488-501. 18. Bartolomeis A, Latte G, Tomasetti C et al. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol Neurobiol. 2014;49(1):484-511. 19. Urban JD, Vargas GA, Von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1):67-77. 20. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237-260. 21. Ijaz S, Bolea B, Davies S et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18(1):275. 22. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60(3):358-403. 23. Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol. 2012;27(1):33-38. 24. Soria-Chacartegui P, Villapalos-García G, Zubiaur P et al. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Front Pharmacol. 2021;12:711940. 25. Kinghorn WA, McEvoy JP. Aripiprazole: Pharmacology, Efficacy, Safety and Tolerability. Expert Rev. Neurotherapeutics. 2005; 5:297-307. 26. Otsuka Pharmaceutical Co, L. Abilify® Prescribing Information. 2014. 27. Abilify® (aripiprazole) tablets [prescribing information]. Tokyo: Otsuka America Pharmaceutical, Inc; (2020). 28. Zhu LR. Comparative analysis of the effects of different doses of aripiprazole on schizophrenia. Worlds Latest Med Inf Dig. (2019) 19:137-138. 29. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635—2647. 30. Быков ЮВ, Беккер РА. Арипризол — уникальный антипсихотик с широким спектром применения в психиатрии: факты и перспективы. Психиатрия и психофармакотерапия. 2017; 19 (4): 30-47. 31. Meltzer HY, Risinger R, Nasrallah HA. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J. Clin. Psychiatry. 2015;76:085-090. 32. Irismar B, Oliveira R De, Elkis H et al. Aripiprazole for patients with schizophrenia and schizoaffective. CNS Sptr. (2008) 14:93-102. 33. Nielsen MO, Kristensen TD, Bojesen KB et al. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses. 2022;13:834333. 34. Clarke LA, Lindenmayer LP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry. 2006;67(4):675-676. 35. James S, Kapugama C, Al-Uzri M. Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia. Case Rep Psychiatry. 2016;2016:7912083. 36. Zajdel P, Kos T, Marciniec K et al. Novel multi-target azine sulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. Eur J Med Chem. 2018;145:790-804. doi: 10.1016/j.ejmech.2018.01.002. 37. Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019;179:55-62. doi: 10.1016/j.pbb. 2019.02.003. 38. Kim SW, Shin IS, Kim JM, Lee JH, Lee YH, Yang SJ, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32:243-249. 39. Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry. 2010;43:50-57. 40. Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. CNS Drugs. 2012;26(11):975-982. 41. Tashiro T. Improvement of a patient's circadian rhythm sleep disorders by aripiprazole was associated with stabilization of his bipolar illness. J Sleep Res. 2017;26(2):247-250. doi: 10.1111/jsr.12496. 42. Matsui K, Takaesu Y, Inoue T, Inada K, Nishimura K. Effect of aripiprazole on non-24-hour sleep-wake rhythm disorder comorbid with major depressive disorder: a case report. Neuropsychiatr Dis Treat. 2017;13:1367-1371. doi: 10.2147/NDT.S136628. 43. Omori Y, Kanbayashi T, Sagawa Y et al. Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation. Neuropsychiatr Dis Treat. 2018;14:1281-1286. doi: 10.2147/NDT.S158865. 44. Takaki M, Ujike H. Aripiprazole is effective for treatment of delayed sleep phase syndrome comorbid with schizophrenia or bipolar disorder: results of randomized controlled study. Clin Neuropharmacol. 2021;37(4):123-124. 45. Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol. 2009;12(7):941-952. 46. Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol. 2012;357(1-2):101-107. 47. Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta- analysis. Sci Rep. 2016;6:25998. 48. Taipale H, Solmi M, Lähteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883-891. 49. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57(1):49-54. 50. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342. 51. Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs. 2018;32(4):351-366. 52. Galbally M, Frayne J, Watson SJ, Snellen M. Aripiprazole and pregnancy: a retrospective, multicentre study. J Affect Disord. 2018;238:593-596. 53. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714-717. 54. Sheldrick AJ, Gründer G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry. 2008;41(4):160. 55. Chang JS, Ahn Y, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69: 720—731. 56. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29: 165—169. 57. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115—1125. 58. Fan X, Borba CP, Copeland P, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127: 217—226. 59. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-542. 60. Correll CU, Agarwal V, Cohen D, De Hert M, Nielsen J. Selective effects of individual antipsychotic cotreatments on cardiometabolic and hormonal risk status: results from a systematic review and meta-analysis. Schizophr Bull. 2013;39:S29-S30. 61. Tracy DK, Sendt KV, Shergill SS. Antipsychotic polypharmacy: still dirty, but hardly a secret. A systematic review and clinical guide. Curr Psychopharmacology. 2013;2(2):143-171. 62. Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-1403. 63. Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res. 2015;62:38-47. 64. Galling B, Roldan A, Rietschel L et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016;15(5):591-612. 65. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69: 1046—1056. 66. Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013; 146: 190—195. 67. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947—956. 68. Nasrallah HA, Aquila R, Stanford AD et al. Metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil. Psychopharmacol. Bull. 2017;47:35-43.